- Home
- IBM vs GILD Comparison
IBM vs GILD Comparison
Compare IBM & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBM | GILD |
|---|---|---|
| Founded | 1911 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.7B | 168.6B |
| IPO Year | 2012 | 2003 |
Fundamental Metrics
Financial Performance| Metric | IBM | GILD |
|---|---|---|
| Price | $284.84 | $129.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $293.33 | $148.39 |
| AVG Volume (30 Days) | ★ 9.8M | 5.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.98% | 2.55% |
| EPS Growth | 73.72 | ★ 1684.21 |
| EPS | 1.28 | ★ 1.61 |
| Revenue | ★ $67,535,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $6.40 | $4.68 |
| Revenue Next Year | $4.60 | $6.04 |
| P/E Ratio | $235.96 | ★ $80.23 |
| Revenue Growth | 7.62 | ★ 9.98 |
| 52 Week Low | $212.34 | $107.19 |
| 52 Week High | $332.46 | $157.29 |
Technical Indicators
Market Signals| Indicator | IBM | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 43.90 |
| Support Level | $268.05 | $128.33 |
| Resistance Level | $314.76 | $137.35 |
| Average True Range (ATR) | 14.11 | 3.01 |
| MACD | 5.83 | -0.18 |
| Stochastic Oscillator | 57.44 | 27.44 |
Price Performance
Historical ComparisonAbout IBM International Business Machines Corporation
Incorporated in 1911, International Business Machines, or IBM, is one of the oldest technology companies in the world. It provides software, IT consulting services, and hardware to help business customers modernize their technology workflows. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which includes 95% of all Fortune 500 companies. IBM's products, including Red Hat, watsonx, and mainframes, handle some of the world's most important data workloads in areas like finance and retail.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).